- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04122430
Risk of Venous Thromboembolism in Patients Receiving First-Line Chemotherapy for Disseminated Germ Cell Tumours (G3 RPLN PBC)
Risk of Venous Thromboembolism in Patients Receiving First-Line Chemotherapy for Disseminated Germ Cell Tumours - a Multi-Site Retrospective Cohort Study as Part of the Global Germ-Cell Cancer Group (G3) Consortium
Recent data (Srikanthan and Tran et al. JCO 2014, in press) have demonstrated that the presence of large retroperitoneal lymph node metastases on baseline staging scans (measuring >5cm in axial dimension) are associated with significantly increased risk of venous thromboembolism in patients receiving first line chemotherapy for disseminated germ cell tumours.
This study, a G3 collaborative effort, aims to confirm these findings in a large multi-national validation cohort.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Recent data (Srikanthan and Tran et al. JCO 2014, in press) have demonstrated that the presence of large retroperitoneal lymph node (RPLN) metastases on baseline staging scans (measuring >5cm in axial dimension) are associated with significantly increased risk of venous thromboembolism (VTE) in patients receiving first line chemotherapy for disseminated germ cell tumours (GCT).
This study, a G3 collaborative effort, aims to confirm these findings in a large multi-national validation cohort.
Primary objective:
To validate the association between large RPLN metastases (measuring >5cm in axial dimension) and increased risk of VTE during and immediately after completion of (within 90 days) first line chemotherapy for disseminated GCT.
Secondary objectives:
- To assess the discriminatory accuracy for VTE of both large RPLN metastases and high-risk Khorana score (defined as > 3)
- To determine the incidence of VTE in patients with disseminated GCT receiving first line chemotherapy at baseline, during chemotherapy and immediately following chemotherapy
- To determine the incidence of VTE during and immediately after chemotherapy in patients receiving prophylactic anticoagulation during first line chemotherapy for disseminated GCT
- To determine the incidence of major bleeding in patients who received prophylactic anticoagulation versus those who did not
- To determine overall survival at 12 months, 3 years and 5 years for patients who developed VTE compared to those who did not No identifying data (e.g. name, hospital UR, address) will be collected.
Data will be collected by retrospective review of the medical chart.
When assessing for the presence of large RPLN as a risk factor for VTE, only the maximal diameter of the long axis of the largest retroperitoneal lymph node metastasis will be recorded. Where the exact measurement is not available, it should be recorded whether the maximal diameter of the largest RPLN measures >5cm or <5cm. The representative value for large RPLN should NOT include the combination of all maximal diameters of all RPLN metastases.
Regarding the pre-chemotherapy values for hemoglobin, platelet count and leukocyte count, these must have been conducted within 30 days of initiation of chemotherapy. The highest serum Creatinine observed during the course of chemotherapy should also be recorded - this is not necessarily the pre-chemotherapy serum Creatinine, as the highest value may have occurred during chemotherapy.
A VTE event is defined as either deep vein thrombosis (DVT) or pulmonary embolism (PE). Superficial venous thrombosis or thrombophlebitis will not be considered as a VTE event. Only bleeding events requiring medical intervention will be recorded.
Data collection will cover the period from the start of curative first line chemotherapy until 90 days following completion of chemotherapy. Any VTE event that is present at baseline (i.e. start of first line chemotherapy) will be recorded. Additionally, any VTE event that occurs within 90 days of completion of chemotherapy will be recorded; this allows recording of incidental VTE noted on post-chemotherapy restaging scans. Distinction will be made for VTE that occurs following post-chemo surgery (post-op) that is performed within the 90 day timeframe.
Data collection should be completed by December 31, 2015 and de-identified data forwarded to the Principal Investigator for data analysis before January 30, 2015.
The aggregated data will be used for study reports, and where appropriate conference presentations and peer-reviewed manuscript(s). In addition, the findings may be used to inform the design of a subsequent prospective trial of prophylactic anticoagulation.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Victoria
-
Parkville, Victoria, Australia, 3052
- Walter and Eliza Hall Institute of Medical Research
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Men with disseminated GCT (AJCC Stage IS, 2, or 3) who have received first line chemotherapy with curative intent for disseminated GCT.
Clinical data available from chemotherapy initiation to at least 90 days following completion of chemotherapy (patients who died prior to 90 days will be included in this study) and initiated chemotherapy between 1-January-2000 and 31-December-2014.
Description
Inclusion Criteria:
- Men with disseminated GCT (AJCC Stage IS, 2, or 3)
- Received first line chemotherapy with curative intent for disseminated GCT
- Clinical data available from chemotherapy initiation to at least 90 days following completion of chemotherapy (patients who died prior to 90 days will be included in this study)
- Initiated chemotherapy between 1-January-2000 and 31-December-2014* *Data collection from consecutive patients initiating chemotherapy during a defined period within the specified timeframe is acceptable (e.g. patient data from 5-year period starting 1-January-2008 and ending 31-December-2012 is acceptable)
Exclusion Criteria:
- Prior chemotherapy for GCT (including use of adjuvant chemotherapy or curative chemotherapy for prior diagnosis of disseminated GCT).
- History of secondary malignancy (excluding non-melanoma superficial skin cancers)
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
GCT treated with first line chemotherapy
Men with disseminated Germ Cell Tumours-GCT (AJCC Stage IS, 2, or 3) and have received first line chemotherapy with curative intent for disseminated GCT . |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To validate the association between large RPLN metastases (measuring >5cm in axial dimension) and increased risk of VTE during and immediately after completion of (within 90 days) first line chemotherapy for disseminated GCT
Time Frame: March 2016
|
March 2016
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To assess the discriminatory accuracy for VTE of both large RPLN metastases and high-risk Khorana score (defined as > 3)
Time Frame: March 2016
|
March 2016
|
To determine the incidence of VTE in patients with disseminated GCT receiving first line chemotherapy at baseline, during chemotherapy and immediately following chemotherapy
Time Frame: March 2016
|
March 2016
|
To determine the incidence of VTE during and immediately after chemotherapy in patients receiving prophylactic anticoagulation during first line chemotherapy for disseminated GCT
Time Frame: March 2016
|
March 2016
|
To determine the incidence of major bleeding in patients who received prophylactic anticoagulation versus those who did not
Time Frame: March 2016
|
March 2016
|
To determine overall survival at 12 months, 3 years and 5 years for patients who developed VTE compared to those who did not.
Time Frame: March 2016
|
March 2016
|
Collaborators and Investigators
Investigators
- Principal Investigator: Ben Tran, Medicine, Walter and Eliza Hall Institute of Medical Resaerch
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Endocrine System Diseases
- Gonadal Disorders
- Endocrine Gland Neoplasms
- Genital Neoplasms, Male
- Testicular Diseases
- Embolism and Thrombosis
- Neoplasms, Germ Cell and Embryonal
- Testicular Neoplasms
- Thromboembolism
- Venous Thromboembolism
Other Study ID Numbers
- QA2015168
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Testicular Neoplasms
-
Haukeland University HospitalKarolinska University Hospital; Oslo University Hospital; University Hospital... and other collaboratorsRecruitingSeminoma | Testicular Germ Cell Cancer | Non-Seminoma Testicular Cancer | Stage I Testicular Cancer | Stage II Testicular Cancer | Stage III Testicular Cancer | Stage IV Testicular Cancer | Relapse Testicular CancerNorway, Sweden
-
University Medical Center GroningenDutch Cancer SocietyCompletedNon-seminomatous Testicular CancerNetherlands
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedTesticular Seminoma | Testicular Yolk Sac Tumor | Childhood Malignant Ovarian Germ Cell Tumor | Childhood Malignant Testicular Germ Cell Tumor | Ovarian Embryonal Carcinoma | Ovarian Yolk Sac Tumor | Testicular Embryonal Carcinoma | Ovarian Choriocarcinoma | Ovarian Mixed Germ Cell Tumor | Testicular Choriocarcinoma and other conditionsUnited States
-
SWOG Cancer Research NetworkNational Cancer Institute (NCI)RecruitingSeminoma | Germ Cell Tumor | Metachronous Malignant Neoplasm | Stage I Testicular Cancer AJCC v8 | Stage IA Testicular Cancer AJCC v8 | Stage IB Testicular Cancer AJCC v8 | Stage IS Testicular Cancer AJCC v8Canada, United States, Guam
-
Erasmus Medical CenterRecruitingQuality of Life | Testicular Germ Cell Tumor | Testicular CancerNetherlands
-
University Medical Center GroningenDutch Cancer SocietyRecruitingTesticular CancerNetherlands
-
Radboud University Medical CenterCompletedTesticular CancerNetherlands
-
Centre Hospitalier Universitaire de NiceTerminatedTesticular CancerFrance
-
National Cancer Institute (NCI)CompletedTesticular CancerUnited States
-
Eastern Mediterranean UniversityCompleted
Clinical Trials on Review of Health Information
-
Duke UniversityDuke Cancer InstituteCompleted
-
University Hospital of SplitCroatian Science FoundationCompletedUnderstanding Cochrane Systematic ReviewsCroatia
-
VA Office of Research and DevelopmentRegenstrief Institute, Inc.CompletedCardiovascular Diseases | Heart Failure | Diabetes Mellitus | Asthma | OsteoporosisUnited States
-
Taipei Medical University WanFang HospitalNo longer availableValuable Suggestions to Improve Health Care Quality Transparent and Accessible Medical Care
-
University of PennsylvaniaCompletedBehavioral Variant of Frontotemporal Dementia | Caregiver Stress SyndromeUnited States
-
Thomas Jefferson UniversityNational Cancer Institute (NCI)TerminatedHypertension | Diabetes Mellitus | Diabetes
-
Indiana UniversityMerck Sharp & Dohme LLCCompletedHuman Papillomavirus VaccinationUnited States
-
University of PittsburghCompleted
-
University of Missouri-ColumbiaNational Library of Medicine (NLM)CompletedDepression | HIV Infections | Hypertension | Obesity | Diabetes Mellitus | Back Pain | Urinary Incontinence | Irritable Bowel Syndrome | Insomnia | Asthma | Anxiety | Sinusitis | Shoulder Pain | Allergic Rhinitis | Urinary Tract Infection | Vaginitis | Bursitis | Hyperlipidemia | Esophageal Reflux | Benign Prostatic Hypertrophy | Osteoporosis... and other conditionsUnited States
-
University of Missouri-ColumbiaNational Library of Medicine (NLM)CompletedDepression | Coronary Artery Disease | HIV Infections | Smoking Cessation | Hypertension | Obesity | Diabetes Mellitus | Chronic Obstructive Pulmonary Disease | Osteoarthritis | Hypothyroidism | Back Pain | Urinary Incontinence | Irritable Bowel Syndrome | Diarrhea | Migraine Disorders | Cough | Sleep Initiation and Maintenance... and other conditions